Lataa...
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtinib, midostaurin, AC220, KW-2449, sorafenib, and sunitinib) for potency against mutant and wild-type FLT3, as well as for cytotoxic effect against a series of primary blast samples obtained from patients with acute myeloi...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2826764/ https://ncbi.nlm.nih.gov/pubmed/20007803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-09-242859 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|